Tennessee House Bill HB1242

Tennessee 2023-2024 Regular Session

• Introduced: 1/31/23
• Refer: 2/2/23
• Refer: 3/14/23
• Refer: 3/28/23
• Refer: 4/18/23
• Engrossed: 4/21/23
• Enrolled: 4/25/23
• Passed: 5/11/23
• Chaptered: 5/24/23

Caption

AN ACT to amend Tennessee Code Annotated, Title 39 and Title 40, relative to drug offenses.

Impact

The enactment of HB 1242 significantly impacts drug offense laws in Tennessee. It classifies possession of xylazine as a Class A misdemeanor, while the manufacture or delivery of the drug is categorized as a Class C felony. By establishing clear legal definitions and penalties for xylazine-related offenses, this bill seeks to provide law enforcement with the tools necessary to tackle the growing problem of this drug's potential abuse. Furthermore, the bill delineates lawful uses of xylazine in veterinary contexts, ensuring that legitimate practices are not adversely affected.

Summary

House Bill 1242 was introduced to address the growing concern over the drug xylazine, and it amends Tennessee Code Annotated, Title 39 and Title 40 related to drug offenses. Under this legislation, it becomes an offense to knowingly possess, manufacture, deliver, or sell xylazine, with specific exceptions for legitimate veterinary practices and prescribed uses. This bill aims to combat the issues associated with the misuse of this substance, which has been increasingly linked to various public health and safety threats.

Sentiment

The sentiment surrounding HB 1242 appears to be broadly supportive, likely due to the recognition of the need to address new and emerging drug threats. Legislators emphasized the urgency of tackling the issues posed by xylazine, given its increasing prevalence. However, some concerns were raised regarding the potential implications for veterinary practices, with discussions focusing on ensuring that veterinarians can still operate effectively without being penalized under the new regulations.

Contention

Notable points of contention include the balance between curbing drug misuse and preserving legitimate veterinary applications of xylazine. While the bill provides necessary legal frameworks to punish illicit activities concerning xylazine, it is vital for the legislation to clearly differentiate between criminal use and legitimate medical applications. This nuance was a focal point during discussions, with advocates for animal health stressing the importance of maintaining access to xylazine for legitimate veterinary needs to prevent any negative impact on animal care.